专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2015112601A1 MODIFIED RELEASE FORMULATIONS OF PRIDOPIDINE 审中-公开
标题翻译： PRIDOPIDINE的改良释放配方
公开(公告)号：WO2015112601A1
公开(公告)日：2015-07-30
申请号：PCT/US2015/012248
申请日：2015-01-21
申请人： IVAX INTERNATIONAL GMBH , TEVA PHARMACEUTICALS USA, INC. , LICHT, Daniella , LOVINGER, Ioana , GUILATT, Laura Yehudit , BASSAN, Merav
发明人： LICHT, Daniella , LOVINGER, Ioana , GUILATT, Laura Yehudit , BASSAN, Merav
IPC分类号： A61K31/451 , C07D211/20 , C07D211/24
CPC分类号： A61K31/451 , A61K9/1617 , A61K9/1652 , A61K9/2009 , A61K9/2054 , A61K9/2059 , A61K9/2068
摘要： The subject invention provides a modified release solid oral dosage form comprising a therapeutically effective amount of Pridopidine or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable rate controlling excipient, wherein the solid oral dosage form provides an in vivo plasma pridopidine concentration profile having a Mean C max of about 1,400 ng/ml or less. The subject invention also provides a method of treating an individual afflicted with a neurodegenerative disease or disease related to dopamine, comprising once daily administration of a modified release solid oral dosage form.
摘要翻译：本发明提供了一种包含治疗有效量的施多替啶或其药学上可接受的盐和至少一种药学上可接受的速率控制赋形剂的改良释放固体口服剂型，其中所述固体口服剂型提供了体内血浆丙泊德定浓度分布，其具有平均Cmax约为1400ng / ml或更低。本发明还提供了治疗患有与多巴胺相关的神经变性疾病或疾病的个体的方法，其包括每日一次施用改良释放固体口服剂型。

2. 发明申请

WO2014205229A8 USE OF HIGH DOSE PRIDOPIDINE FOR TREATING HUNTINGTON'S DISEASE 审中-公开
公开(公告)号：WO2014205229A8
公开(公告)日：2014-12-24
申请号：PCT/US2014/043204
申请日：2014-06-19
申请人： IVAX INTERNATIONAL Gmbh , TEVA PHARMACEUTICALS USA, INC. , BASSAN, Merav , EYAL, Eli , HAGAI, Esther, Lukasiewicz , SVEINSDOTTER TEIGE WICKENBERG, Anna, Kristina
发明人： BASSAN, Merav , EYAL, Eli , HAGAI, Esther, Lukasiewicz , SVEINSDOTTER TEIGE WICKENBERG, Anna, Kristina
IPC分类号： A61K31/445
摘要： This invention provides a method of treating a human patient afflicted with Huntington's disease, comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof such that greater than 135 mg of pridopidine is administered to the patient per day. This invention further provides a method of treating a human patient afflicted with Huntington's disease, comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine hydrochloride such that greater than 90 mg of pridopidine is administered to the patient per day.

3. 发明申请

WO2015168284A1 ALBUMIN-BCHE IN DETOXIFICATION OF NEUROTOXINS 审中-公开
标题翻译： ALBUMIN-BCHE在脱氧神经毒素中的应用
公开(公告)号：WO2015168284A1
公开(公告)日：2015-11-05
申请号：PCT/US2015/028291
申请日：2015-04-29
申请人： TEVA PHARMACEUTICAL INDUSTRIES LTD. , BASSAN, Merav , GROSS, Aviva , SINGH, Mallika , SEAVEY, Matthew, M. , BOCK, Jason , ELIAZ, Rom, E.
发明人： BASSAN, Merav , GROSS, Aviva , SINGH, Mallika , SEAVEY, Matthew, M. , BOCK, Jason , ELIAZ, Rom, E.
IPC分类号： C12N9/18
CPC分类号： C12N9/18 , A61K31/15 , A61K38/465 , C07K2319/31 , C12Y301/01008 , A61K2300/00
摘要： The present invention provides the recombinant fusion protein of SEQ ID No :1. and a method of treating a mammal for exposure to a neurotoxin or for preventing or ameliorating the Neurotoxic Symptoms of exposure to neurotoxin which comprises administering an effective amount of the recombinant fusion protein of SEQ ID No :1. SEQ ID No:1 is a fully recombinant fusion polypeptide composed of the mature form of human serum albumin (HSA) fused at its amino terminus to the carboxy- terminus of a truncated and mutated human BChE.
摘要翻译：本发明提供了SEQ ID No：1的重组融合蛋白。以及治疗哺乳动物暴露于神经毒素或用于预防或改善暴露于神经毒素的神经毒性症状的方法，其包括施用有效量的SEQ ID No：1的重组融合蛋白。 SEQ ID No：1是由其血清白蛋白（HSA）的成熟形式组成的完全重组融合多肽，其在其氨基末端与截短和突变的人类BChE的羧基末端融合。

4. 发明申请

WO2016138130A1 USE OF PRIDOPIDINE TO IMPROVE COGNITIVE FUNCTION AND FOR TREATING ALZHEIMER'S DISEASE 审中-公开
标题翻译：使用孕激素改善认知功能和治疗阿尔茨海默病
公开(公告)号：WO2016138130A1
公开(公告)日：2016-09-01
申请号：PCT/US2016/019357
申请日：2016-02-24
申请人： TEVA PHARMACEUTICALS INTERNATIONAL GMBH , THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM , GEVA, Michal , BEZPROZVANNY, Ilya , BASSAN, Merav , HAYDEN, Michael
发明人： GEVA, Michal , BEZPROZVANNY, Ilya , BASSAN, Merav , HAYDEN, Michael
IPC分类号： A61P25/28
CPC分类号： A61K31/451 , C07D211/24 , C07D211/42 , C07D211/52
摘要： This invention provides a method of improving cognitive function in a subject comprising periodically administering to the subject an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to improve a cognitive function in the subject. The invention also provides a method of treating a subject afflicted with Alzheimer's disease, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to treat the subject.
摘要翻译：本发明提供一种改善受试者的认知功能的方法，其包括向受试者周期性施用一定量的有效改善受试者的认知功能的派多定或其药学上可接受的盐。本发明还提供了治疗患有阿尔茨海默病的受试者的方法，其包括向受试者周期性施用包含有效治疗受试者的一定量的派多定或其药学上可接受的盐的药物组合物。

5. 发明申请

WO2014093354A1 FUSION OF HUMAN GROWTH HORMONE AND ALBUMIN, FORMULATION AND USES THEREOF 审中-公开
标题翻译：人类生长激素和阿尔布辛的融合，配方及其用途
公开(公告)号：WO2014093354A1
公开(公告)日：2014-06-19
申请号：PCT/US2013/074145
申请日：2013-12-10
申请人： TEVA PHARMACEUTICAL INDUSTRIES LTD. , BROWN, Kurt , BASSAN, Merav
发明人： BROWN, Kurt , BASSAN, Merav
IPC分类号： A61K38/00 , C12P21/04
CPC分类号： A61K38/27 , A61K2300/00
摘要： The present invention provides a method of treating a human patient in need of growth hormone therapy by periodically administering to the human patient for more than two weeks an effective amount of a composition comprising a pharmaceutically acceptable carrier and a fusion protein whose amino acid sequence is set forth as SEQ ID NO: 1, so as to thereby treat the human patient. The present invention also provides a method of treating a human patient in need of growth hormone therapy by administering to the human patient, in a clinically effective regimen, a clinically effective dose of a composition comprising a pharmaceutically acceptable carrier and a fusion protein whose amino acid sequence is set forth as SEQ ID NO: 1, wherein the clinically effective dose and clinically effective regimen are selected by a series of steps.
摘要翻译：本发明提供了一种治疗需要生长激素治疗的人类患者的方法，其通过向人类患者定期施用两周以上有效量的包含药学上可接受的载体和其氨基酸序列设定的融合蛋白的组合物如SEQ ID NO：1所示，从而治疗人类患者。本发明还提供了一种治疗需要生长激素治疗的人类患者的方法，其通过在临床有效方案中向人类患者施用临床有效剂量的包含药学上可接受的载体和融合蛋白的组合物，所述组合物的氨基酸序列如SEQ ID NO：1所示，其中通过一系列步骤选择临床有效剂量和临床有效方案。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式